Acetamides: chemotherapeutic agents for inflammation-associated cancers

J Chemother. 2016 Aug;28(4):255-65. doi: 10.1179/1973947815Y.0000000060.

Abstract

Now clear evidences are available to support the hypothesis that inflammation accelerates the conditions including events and molecules that reach to various types of cancers. Inflammation is a normal response to infection containing the innate and adaptive immune systems. However, when allowed to continue, unresolved, perturbation of cellular microenvironment takes place; therefore, it leads to adaptations in genes that are linked to cancer. In addition, a lot of data are accessible confirming the concept that tumour microenvironment is orchestrated by various inflammatory cells and goes to neoplastic process and finally invasion, migration and metastasis. However, infiltrations of leucocytes lead to angiogenesis, propagation and invasion. An inflammatory microenvironment that perhaps fostering impact of angiogenesis include cytokines, chemokines, enzymes and growth factors that play key role for expansion and invasion of cancer cells. This insight highlights the pathogenesis of inflammation-associated cancers and also touches and fosters the role of acetamides for the treatment and chemoprevention of carcinomas that are allied with inflammation.

Keywords: Angiogenesis; COX-2; Chemotherapy; Inflammation; LOX-2; Phenoxyacetamide derivatives.

Publication types

  • Review

MeSH terms

  • Acetamides / chemistry
  • Acetamides / therapeutic use*
  • Anti-Inflammatory Agents / chemistry
  • Anti-Inflammatory Agents / therapeutic use*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Cell Cycle
  • Cyclooxygenase Inhibitors / chemistry
  • Cyclooxygenase Inhibitors / therapeutic use
  • Humans
  • Inflammation / complications*
  • Neoplasms / drug therapy
  • Neoplasms / immunology*

Substances

  • Acetamides
  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Cyclooxygenase Inhibitors